Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $810.00 by Analysts at Guggenheim
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price cut by investment analysts at Guggenheim from $940.00 to $810.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 33.75% from the company’s current price. Several […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price cut by investment analysts at Guggenheim from $940.00 to $810.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 33.75% from the company’s current price. Several […]
